Screening for safe opening of universities under

Omicron and Delta variants of COVID-19:

When less is more

Marie Jeanne Rabil^{1,*,@}, Sait Tunc^{1,@}, Douglas R. Bish^{2,+}, and Ebru K. Bish^{2,+}

¹Virginia Polytechnic Institute and State University, Grado Department of Industrial and Systems Engineering, Blacksburg, 24061, United States of America
²The University of Alabama, Department of Information Systems, Statistics, and Management Science, Culverhouse College of Business, Tuscaloosa, 35487, United States of America
*mariejeanne@vt.edu
@these authors contributed equally to this work
*these authors contributed equally to this work

ABSTRACT

As new COVID-19 variants emerge, and disease and population characteristics change, screening strategies may also need to change. We develop screening guidelines for the safe opening of college campuses, considering COVID-19 infections/hospitalizations/deaths; peak daily hospitalizations; and the tests required. Our compartmental model simulates disease spread on a college campus under co-circulating variants with different disease dynamics, considering: (i) the heterogeneity in disease transmission and outcomes for faculty/staff and students based on vaccination status and level of natural immunity; and (ii) variant- and dose-dependent vaccine efficacy. Using the Spring 2022 academic semester as a case study, we study various routine screening strategies, and find that screening the faculty/staff less frequently than the students, and/or the boosted and vaccinated less frequently than the unvaccinated, may avert a higher number of infections per test, compared to universal screening of the entire population at a common frequency. We also discuss key policy issues, including the need to revisit the mitigation objective over time, effective strategies that are informed by booster coverage, and if and when screening alone can compensate for low booster coverage.

Introduction

Two years into the pandemic, and, COVID-19, through emerging variants, continues to pose a threat to in-person education in academic institutions. Once again, universities and colleges are facing an abundance of COVID-19 cases on their campuses [1], and are finding themselves in a position to reformulate/reoptimize their infection mitigation strategies (e.g., vaccination mandates, 17

13

14

11

12

2

routine screening, face masking, and social distancing policies, hybrid learning practices), to adapt to the characteristics of the new Delta and Omicron variants, with an eye on future variants yet to come. A continuous reformulation of infection mitigation strategies will remain essential as the pandemic continues to evolve with new virus variants, and as the current interventions (vaccines, testing kits, masks), their availability, and efficacy continue to change. With COVID-19 vaccination and testing kits already developed, the current challenges for effective mitigation differ from those faced at the beginning of the pandemic. Now the mitigation strategies need to account for new virus variants with different transmission and disease dynamics [2, 3], and vaccine effectiveness that is not only imperfect and decaying over time [4], but is also variant-dependent.

Indeed, as the year 2021 came to an end, the then-dominating Delta variant of the virus started to be replaced with the 25 emerging Omicron variant, which, by the beginning of 2022, has become the primary variant that was causing more than 70% 26 of all COVID-19 infections in the United States (U.S.) [5]. From an intervention strategy perspective, there are important 27 differences between the Delta and Omicron variants. While the Omicron variant spreads easier than the Delta variant (even 28 among the vaccinated), it is less likely to cause severe illness [6], especially in vaccinated and boosted populations [7]. Further, 29 while this new period of the pandemic is marked by wide availability of the vaccine, it is also marked by vaccine hesitancy in 30 certain groups [8], and, once more, by the scarcity of the testing resources [9]. As a result, there is an ongoing need to utilize 31 the limited testing resources in the most effective and efficient way for routine screening of the asymptomatic individuals, 32 who can still transmit the disease [10]. Motivated by these observations, in this paper we build and analyze a compartmental 33 model, to develop optimal customized screening strategies for college/university campuses, considering the characteristics of 34 the campus population (e.g., vaccine intake rates, campus size, age distribution), and of the disease (e.g., circulating variant(s) 35 and their transmission and disease characteristics, and vaccine effectiveness). 36

The literature on screening and vaccination for infectious diseases is vast, and growing, thanks to the pandemic. We refer 37 the interested reader to the many references in [11, 12, 13, 14, 15, 16] for screening related work, in [17, 18, 19, 20, 21, 22, 38 23, 24, 25, 26, 27] for vaccination related work, and in [28, 29, 30] for screening and vaccination related work; and simply 39 discuss the more recent, Omicron-related works here. The academic literature related to Omicron is still quite limited: [31] 40 develops a compartmental model to predict various outcome metrics related to the Omicron variant under different transmission 41 and severity scenarios, while [32] develops a compartmental model that considers vaccination (including boosters), waning 42 immunity from the vaccine, and different COVID-19 variants (including Omicron), in order to estimate the reduction in 43 transmission rates, and its effect on daily infections, in response to various government policies in Korea. [33] develops a 44 compartmental model to investigate the impact of vaccination coverage on different outcome metrics under the Omicron variant 45 and a less transmissible variant. Importantly, neither work [31, 32, 33] models and studies screening strategies, which is the 46 main focus of our paper. 47

Specifically, we contribute to this stream of literature by building an extended compartmental model to study routine 48 screening strategies, which may be customized based on the vaccination status and/or the demographics of campus residents. 49 To this end, we model each individual's vaccination status using three categories, unvaccinated, fully vaccinated (hereafter, 50

"vaccinated"), and boosted; and consider faculty/staff (hereafter, "faculty") versus student groups. This customization allows us to consider a wide range of routine screening policies, ranging from *universal* (i.e., screening all campus residents with the same frequency), to *partially customized* (i.e., screening only selected vaccination status, with a common frequency), to *fully customized* (i.e., further customizing the screening frequency for each group selected for screening). In addition to campus demographics, our compartmental model also accounts for vaccination coverage (proportion vaccinated/proportion boosted), two circulating variants (Delta and Omicron), and less-than-perfect screening compliance of the campus residents.

We also model imperfect vaccine effectiveness, with effectiveness values that depend on both the variant (Delta versus Omicron) and the vaccination status (vaccinated versus boosted); and a time-dependent disease transmission rate, which varies as the proportion of the infectious population changes over time. Because two variants may be circulating at the same time, vaccine effectiveness, infection transmission rates, and other disease characteristics now become conditional on which variant each individual is exposed to.

These aspects necessitate new modeling approaches in our compartmental model. Using this model, we compare the efficiency and effectiveness of various routine screening strategies based on multiple criteria, including the number of infections/hospitalizations/deaths, and peak infections/hospitalizations. Our model allows a college to conduct a comparative study of various screening strategies, so as to develop their optimal strategy based on total and peak case numbers the college is able to cope with.

Results

The study setting is a hypothetical college with a population of 24,000 (22,500 students and 2,500 faculty/staff), during an 80-day 68 Spring 2022 academic semester that starts in January 2022. Our SEIR (Susceptible, Exposed, Infectious, Removed) framework 69 simulates COVID-19 infection spread, considering different levels of vaccine-induced immunity and natural immunity, and a 70 variety of protective and preventative interventions, including routine screening of the asymptomatic population, vaccination, 71 face masking, symptomatic testing, and isolation of the test-positive cases. Another key aspect of this framework is the 72 modeling that the two variants, Delta and Omicron, can be in circulation simultaneously, with parameter ω_0 representing the 73 proportion (in %) of all COVID-19 infections caused by Omicron, and the remaining $1 - \omega_0$ representing the proportion caused 74 by Delta. We explicitly model that vaccine effectiveness, infection transmission, and disease characteristics are conditional on 75 which variant each individual is exposed to. As the initial conditions, some individuals arrive on campus as fully vaccinated 76 or boosted; we also introduce a number of undetected, asymptotic SARS-CoV-2 infections to the campus at the outset (135 77 students and 9 faculty members, representing 0.6% of each group). 78

Screening Strategy

We first focus on routine screening that is either universal, or customizes only the screening population (Table 1), and postpone the discussion of screening frequency customization until the next section. The base case considers 75% screening compliance, and total vaccination coverage of 82% (64% boosted, 18% vaccinated), with 18% unvaccinated at the start of the semester

67

(Table 2). With regards to variant prevalences, we discuss two important cases that represent the pandemic progression: $\omega_0 = 50\%$, where both Omicron and Delta variants are in circulation in similar rates, which may represent the U.S. during late December 2021 [34]; and $\omega_0 = 95\%$, where Omicron takes over as the predominant variant, which was the case in the U.S. starting in early January 2022 [35].

Impact of Variant Breakdown

87

We study the impact of pandemic progression (i.e., the transition of the dominant variant from Delta to Omicron) on the 88 performance of screening strategies, under 82% total vaccination coverage (with 64% of the population boosted and 18% vaccinated), and 18% unvaccinated. When both Delta and Omicron variants are in circulation at similar rates ($\omega_Q = 50\%$, see 90 Supplementary Table 4), universal screening every 1/2/14 days results in 1.012/4,058/15,458 total infections, and 31/31/142 91 peak daily infections, respectively. If the boosted individuals are excluded from screening, the 1/2/14-day screening strategies 92 yield 7,967/12,168/16,741 total infections, and 45/81/159 peak daily infections, respectively. The strategy that averts the highest 93 number of infections per test is screening the unvaccinated only every 14 days, with 31.6 infections averted per 1,000 tests over 94 no screening (see Fig. 1(a)); furthermore, this strategy also provides the highest reduction in peak infections per test, reducing 95 the peak by 0.9 infections per 1,000 tests over no screening (see Fig. 2(a)). 96

Under $\omega_0 = 50\%$, the strategy that averts the highest number of infections per test depends on the booster coverage. When 64% of the population is boosted and 18% is vaccinated, if the screening frequency of the unvaccinated is set to every 1/2/3/7/14 days, the strategy that averts the highest number of infections per test is screening the unvaccinated and vaccinated every 1/2 days, and screening the unvaccinated only every 3/7/14 days, averting 23.2/27.5/29/31/31.6 infections per 1,000 tests (see Fig. 1(a)), respectively, whereas the strategy that averts the highest number of infections per test with 38% boosted and 44% vaccinated, is screening the vaccinated and unvaccinated every 1/2/3/7 days and screening the unvaccinated only every 14 days, averting 17.6/20.19/20.23/19.3/19.5 infections per 1,000 tests (see Fig. 1(b)), respectively.

When Omicron is the predominant variant ($\omega_0 = 95\%$, see Supplementary Table 5), universal screening every 1/2/14 ¹⁰⁴ days results in 8,568/17,327/22,512 total infections, and 61/222/465 peak daily infections, respectively. When screening ¹⁰⁵ excludes boosted individuals, 1/2/14-day screening yields 21,578/22,111/22,820 total infections, and 312/380/487 peak daily ¹⁰⁶ infections, respectively. Under this scenario, the strategy that averts the highest number of infections per test is the daily ¹⁰⁷ universal screening, averting 11.9 infections per 1,000 tests (see Fig. 1(c)), whereas the strategy that provides the highest ¹⁰⁸ reduction in peak infections per test is screening the unvaccinated every 3 days, which reduces the peak by 1.09 infections per ¹⁰⁹ 1,000 tests (see Fig. 2(c)).

Under $\omega_0 = 95\%$, if the screening frequency of the unvaccinated is every 1/2/3/7/14 days, the strategy that averts the ¹¹¹ highest number of infections per test is 1/2/3/7/14 day universal screening for both the 64% boosted and 18% vaccinated, or the ¹¹² 38% boosted and 44% vaccinated cases, averting 11.4/9.9/7.2/6 and 7.4/5.8/3.8/3 infections per 1,000 tests (see Fig. 1(c) and ¹¹³ Fig. 1(d)), respectively. ¹¹⁴

Impact of Vaccination Status

Next, we study the impact of the proportion boosted on the performance of screening strategies, first for the scenario where 116 Omicron is the predominant variant ($\omega_0 = 95\%$). We consider the scenario with total vaccination coverage of 82% (38%) 117 boosted, 44% vaccinated), hence with 18% unvaccinated. Under this scenario, universal screening every 1/2/14 days result 118 in 13,803/20,241/23,221 total infections, and 143/357/612 peak daily infections, respectively (see Supplementary Table 5), 119 compared to 8,568/17,327/22,512 total, and 61/222/465 peak daily infections, respectively, when 64% of the population is 120 boosted. The strategy that averts the highest number of infections per test is daily universal screening, averting 9.3 infections 121 per 1,000 tests, see Fig. 1(d), whereas the strategy that provides the highest reduction in peak infections per test is screening the 122 unvaccinated every 3 days, which reduces the peak by 1 infection per 1,000 tests (see Fig. 2(d)). 123

The boosted proportion further impacts hospitalizations (see Supplementary Table 5). With a boosted proportion of ¹²⁴ only 38%, universal screening every 1/2/14 days results in 100/133/145 total hospitalizations, and 12/22/29 peak daily ¹²⁵ hospitalizations, respectively; compared to 61/102/118 total, and 6/14/21 peak daily hospitalizations, respectively, when the ¹²⁶ boosted proportion is 64%.

When both Delta and Omicron variants are circulating at similar rates ($\omega_0 = 50\%$, see Supplementary Table 4) and ¹²⁸ 38% of the population is boosted, universal screening every 1/2/14 days results in 1,584/7,478/18,546 infections, and peak ¹²⁹ daily infections of 36/47/219, respectively. If we exclude boosted individuals from screening, 1/2/14-day screening yields ¹³⁰ 6,341/12,932/19,096 infections, and peak daily infections of 36/94/229, respectively. ¹³¹

Customizing the Screening Frequencies

In this section, we study the impact of further customizing the screening frequencies. We first consider that the screening 133 frequency can be customized for each vaccination category included in the screening population, under 82% vaccination 134 coverage (64% boosted, 18% vaccinated). When $\omega_0 = 50\%$, the strategy that averts the highest number of infections per test is 135 screening the unvaccinated every 14 days (see Fig. 3(a)), leading to 31.6 infections averted per 1,000 tests (see Supplementary 136 Table 9). The same strategy also provides the highest reduction in peak infections per test (see Fig. 4(a)), i.e., a reduction 137 of 0.9 infections per 1,000 tests. When $\omega_0 = 95\%$, the strategy that averts the highest number of infections per test is daily 138 screening of the unvaccinated and vaccinated, and 2-day screening of the boosted (see Fig. 3(b)), resulting in 12.4 infections 139 averted per 1,000 tests, with a 4% improvement compared to the most effective universal screening strategy (i.e., the strategy 140 that screens the entire population with the same screening frequency), see Fig. 3(b) and Supplementary Table 9; whereas the 141 strategy that provides the highest reduction in peak infections per test is screening the unvaccinated only every 3 days (see 142 Fig. 4(b)), reducing the peak by 1.09 infections per 1,000 tests. 143

We next consider fully customized screening, where the screening frequency can be customized for each group (faculty versus students) and each vaccination category included in the screening population, under 82% vaccination coverage (64% boosted, 18% vaccinated). When $\omega_0 = 50\%$, the strategy that averts the highest number of infections per test is screening only the unvaccinated students every 14 days (see Fig. 3(c)), leading to 32.5 infections averted per 1,000 tests, with a 2.8%

132

improvement compared to the most effective strategy that customizes the screening population only. The same strategy also 148 provides the highest reduction in peak infections per test (see Fig. 4(c)), with a reduction of 0.93 infections per 1,000 tests, 149 which provides a 3.3% improvement compared to the most effective strategy that customizes the screening population only. 150 When $\omega_0 = 95\%$, the strategy that averts the highest number of infections per test is the daily screening of the unvaccinated and 151 vaccinated students, 2-day screening of the boosted students, and the unvaccinated and vaccinated faculty, and 3-day screening 152 of the boosted faculty, resulting in 12.5 infections averted per 1,000 tests, with a 5% improvement compared to the most 153 effective universal screening strategy (see Fig. 3(d)); whereas the strategy that provides the highest reduction in peak infections 154 per test is screening only the unvaccinated students every 3 days (see Fig. 4(d)), reducing the peak by 1.13 infections per 1,000 155 tests and providing a 3.7% improvement compared to the most effective strategy that customizes the screening population only. 156

Booster Coverage, Vaccine Effectiveness, and Screening Compliance

While screening can be an effective tool for reducing the infection spread, it is uncertain whether aggressive screening, without a 158 high enough booster coverage, would be sufficient for controlling the infection during various phases of the pandemic. We next 159 study the impact of the booster coverage on total infections and total hospitalizations under perfect screening compliance for 160 different Omicron proportions. If $\omega_Q = 50\%$, universal daily screening yields 1,036/894/606/473/295 infections, and 10/10/8/7/5 161 hospitalizations at the end of the semester under booster coverages of 0.2%/20%/50%/75%/82%, respectively, see Fig. 5(a), 162 whereas not performing any routine screening during the semester results in 22,445/21,335/19,036/16,919/15,248 infections, 163 and 142/127/103/87/77 hospitalizations at the end of the semester under booster coverages of 0.2%/20%/50%/75%/82%, 164 respectively, see Fig. 5(a). On the other hand, if $\omega_0 = 95\%$, universal daily screening results in 15,965/12,192/5,901/2,382/1,444 165 total infections, and 127/93/43/20/13 total hospitalizations for booster coverages of 0.2%/20%/50%/75%/82%, respectively, see 166 Fig. 5(b), whereas no screening leads to 23,833/23,704/23,338/22,776/22,601 total infections, and 183/164/134/109/101 total 167 hospitalizations under booster coverages of 0.2%/20%/50%/75%/82%, respectively, see Fig. 5(b). 168

Next, we study the impact of vaccine effectiveness, which is imperfect, decaying over time, and variant-dependent (see 169 Table 3), over several outcomes. When $\omega_0 = 95\%$, even when the entire population is vaccinated (but not boosted) and is 170 screened under perfect compliance, 1/2-day screening leads to 13,755/21,496 total infections, and 70/115 hospitalizations under 171 vaccine effectiveness values reported for Omicron (see Supplementary Table 7). If the vaccine effectiveness for Omicron were 172 as high as for Delta (see Supplementary Table 8), the same level of mitigation efforts would yield 123/327 infections, and 173 1/2 hospitalization(s). In this scenario, the number of infections and hospitalizations would be 690/4,079/9,068, and 4/17/37, 174 respectively, under 3/7/14-day screening (see Supplementary Table 8). The discrepancy between the two scenarios is less 175 striking, but still significant, when the proportion of Omicron is lower, i.e., $\omega_0 = 50\%$, or when the entire population is boosted 176 (see Supplementary Table 8). 177

Recognizing that different campus populations may exhibit different characteristics in their screening compliance, we 178 further investigate the impact of screening compliance. For 82% vaccination coverage (64% boosted, 18% vaccinated) and 179 $\omega_O = 95\%$, increasing the screening compliance of universal screening from 75% to 90% reduces the infections from 8,568 to 180

5,563 for daily screening, and from 17,327 to 15,655 for 2-day screening, see Supplementary Table 6.

Discussion

As new COVID-19 variants emerge, the challenges for effective mitigation of the pandemic in closed communities evolve. ¹⁸³ Considering the Spring 2022 academic semester and the co-circulating Delta and Omicron variants in this period, the results ¹⁸⁴ from the extended compartmental model in this study suggest that routine screening continues to play a key role in the safe ¹⁸⁵ opening and operation of universities. However, allocating the limited screening resources in the most effective manner ¹⁸⁶ requires extensive planning, considering the specific transmission and disease dynamics of the circulating variants, as well as ¹⁸⁷ the vaccination coverage, the imperfect, waning, and variant-dependent immunity from vaccination, and the level of natural ¹⁸⁸ immunity in the population. ¹⁸⁹

As expected, the benefits of routine screening increase as the screening coverage is expanded and screening is more frequent. 190 However, frequent universal screening of the whole campus population may not always be feasible due to the limited testing 191 resources [36], and may not even be preferred by the universities due to the well-known testing fatigue [37]. Thus, designing 192 strategies that yield the highest per-test benefit for various key metrics may provide essential guidelines to universities in 193 establishing effective mitigation policies that are needed for a safe campus environment that is conducive to learning. The 194 results in this paper demonstrate that the screening strategy that averts the highest number of infections per test depends on the 195 booster coverage and the characteristics of the predominant variant. Comparing universal strategies with those that customize 196 the screening population, our results indicate that universal screening is never the most efficient strategy in terms of infections 197 averted per test when both Delta and Omicron variants are in circulation at similar rates, which may represent the U.S. during 198 late December 2021 [34]. On the other hand, when Omicron is the predominant variant, which has been the case in the U.S. 199 since early January 2022 [35], universal screening does provide the highest per-test reduction in infections. In fact, our findings 200 highlight that the higher the proportion of Omicron and the lower the boosted coverage, the more vaccination status categories 201 need to be screened, and at a higher frequency, in order to maximize the infections averted per test. Several factors, including the 202 higher reproduction number of, and the lower vaccine efficiency against, Omicron, and the waning vaccine-induced immunity 203 against both variants, contribute to this finding. Furthermore, we observe that as the proportion of Omicron (versus Delta) 204 decreases, the screening frequency that is needed to maximize the efficiency also decreases. 205

Another key finding is the need for the decision maker to revisit their mitigation objectives as new variants, having different characteristics, emerge. Our results show that when Omicron is the primary circulating variant and screening resources are limited, it might be better to focus on minimizing the peak infections, instead of the total infections, where the latter requires aggressive screening that may not be resource-feasible, or practical, for most universities. We show that screening only unvaccinated individuals (that is, customizing the screening population) is the most efficient strategy in terms of the peak infections averted per test under various Omicron proportions and boosted coverage rates. This finding signifies that when a variant with a higher reproduction number is the dominant strain, allocating the available testing resources to the most

181

vulnerable provides the most efficient response to the pandemic, by "flattening the curve." We need to emphasize, however, that the most efficient strategy, i.e. the strategy that maximizes infections (or peak infections) averted per-test, may not (and in most scenarios will not) minimize the total number of infections. Since increasing the screening coverage and/or frequency always reduces the total number of infections, universities may need to choose their strategy based on sequentially increasing the screening coverage and/or frequency, in the most efficient way, until the expected number of infections is reduced to a tolerable level.

There have been significant discrepancies among U.S. colleges and universities regarding routine screening. For example, 219 some universities conducted universal screening [38], whereas some others customized the screening population based on 220 vaccination status, but still used the same screening frequency for all the screening population [39, 40], yet some others did 221 switch, at some point, to screening the faculty and students with different screening frequencies. For instance, at the beginning 222 of the Spring semester, Boston University required the faculty to be routinely screened once a week, and the students twice 223 a week [41]. Stanford, on the other hand, required students to be screened weekly but exempted the faculty from routine 224 screening at some point in the semester [42]. Comparing screening strategies with varying degrees of customization, our 225 findings demonstrate that customizing both the screening population and the frequency based on vaccination status may avert 226 slightly more infections per test over universal strategies, or strategies that customize the screening population only, especially 227 when it is feasible to screen the unvaccinated at higher frequencies, and when both Delta and Omicron are in circulation at 228 similar rates. In this case, the most efficient strategy calls for screening the vaccinated and the boosted less frequently than the unvaccinated, and perhaps not screening the boosted at all. This finding is significant, as it implies that, through customization, 230 a less aggressive strategy (that screens a smaller portion of the population) can provide higher per-test efficiency than universal 231 screening. 232

Full customization, which considers both the vaccination status and faculty versus student groups further increases the 233 infections averted per test, over customization based on vaccination status alone. While the improvement is small, the main 234 message is again that the decision maker can achieve higher per-test benefits with less screening. In particular, when full 225 customization is considered, the most efficient strategy (for infections averted per test) recommends the faculty to be screened either less frequently than the students, or not at all. In terms of the peak number of infections averted per test, on the 237 other hand, customizing the screening population already provides a highly efficient strategy, and further customizing the 238 screening frequency does not offer significant benefits: screening only the unvaccinated remains the dominating strategy. 239 Overall, our results suggest that allowing customization of both the screening population and the frequency based on population 240 characteristics may indeed yield more efficient strategies; equally important is the fact that these customized strategies may also 241 lower the required testing resources during the semester. This is because in many cases efficient customized strategies call for 242 some groups to be either tested with very low frequency, or not at all, and this may even reduce the logistical complexity of 243 screening, which was contrary to our initial intuition about customized strategies. 244

As the vaccine-induced immunity in the population wanes over time and/or new variants, which are more resistant to the 245

available vaccines, emerge, as was the case at the beginning of 2022, important policy questions arise on whether on-campus 246 screening would be sufficient for infection control, and how these efforts should be adjusted based on the booster coverage at the 247 start of the semester. Our results indicate that when both Delta and Omicron are in circulation at similar rates, aiming for both 248 aggressive screening and high levels of booster coverage may be redundant; screening alone may even be able to compensate 249 for a lack of an appropriate booster coverage at the start of the semester. Ideally, integrating moderate levels of booster coverage 250 and screening can provide a highly effective, yet not aggressive, mitigation effort to keep both the number of infections and 251 hospitalizations under control. When Omicron is the primary circulating variant, however, integrating boosters and screening 252 is key for effective mitigation, as none of these efforts would be sufficient, on its own, for controlling the infection, even 253 when implemented at an aggressive level. Accordingly, our results suggest that both adequate booster coverage and routine 254 screening are essential for a safe opening of university campuses, considering the diminishing vaccine effectiveness over time 255 and new vaccine-resistant variant threats. From a practical perspective, integrated screening and booster efforts work especially 256 well towards creating an academic environment that is conducive to in-person learning, because the system is unlikely to be 257 overwhelmed by a large volume of students and/or faculty missing from the classroom due to an active infection or isolation 258 orders; this can also reduce the potential testing fatigue. 259

Finally, our findings from the sensitivity analyses suggest that if new vaccines are developed with high effectiveness against emerging variants – at levels comparable to the effectiveness of current vaccines over the Delta variant– it may be possible to keep both the infections and hospitalizations under control, even with lenient screening, as long as sufficient levels of vaccination/booster coverage are maintained. Our analysis also indicates that, although higher screening compliance leads to fewer infections, its impact is not substantial, as long as the compliance is kept at a reasonable level (e.g., 75% in our study).

Methods

Study Design and Parameters

Our SEIR (Susceptible, Exposed, Infectious, Removed) model extends the compartmental framework in [29] in the following 267 ways: We consider a setting where two variants of the virus (Delta and Omicron) might be in circulation simultaneously, and 268 model both vaccine-induced immunity and natural immunity (i.e., acquired based on a prior infection), as well as imperfect 269 vaccine effectiveness that depends on both the variant (Delta versus Omicron) and the vaccination status (vaccinated versus 270 boosted). Due to two circulating variants, vaccine effectiveness, infection transmission, and disease characteristics now become 271 conditional on which variant each individual is exposed to. This setting necessitates the modeling of the heterogeneity in 272 the campus population not only in terms of faculty and student groups (indexed by "f, s," respectively), but also based on 273 vaccination status (unvaccinated, vaccinated, and boosted, indexed by "u, v, b," respectively), and the presence or absence of 274 natural immunity. The model simulates the probabilistic transitioning of individuals through different health and vaccination states (compartments), governed by a series of difference equations, group-dependent and/or vaccination status-dependent 276 transition probabilities. In particular, each individual transitions through some subset of the following health states: exposure to

265

the virus, symptom development or asymptomatic infection, recovery and natural immunity (with or without knowledge of the infection), hospitalization, and death; both disease transmission and disease outcome rates depend on the variant, faculty versus student group, and vaccination status, see the Supplementary information text for details. We consider the following interventions:

- Isolation and face masking: All symptomatic subjects, and positive-testing subjects during routine screening immediately go into isolation. Indoor face masking is required for all subjects.
- Vaccination: We consider two-dose vaccines (i.e., Pfizer and Moderna, which represent around 96% of the vaccines 284 administered in the U.S. as of March 13, 2022 [43]), and model each subject's vaccination status through the following 285 categories: unvaccinated, vaccinated (fully vaccinated with a two-dose vaccine prior to August 2021), boosted (fully 286 vaccinated, and boosted in January 2022). We do not consider the population that has received only one dose of a two-dose vaccine. Each subject starts the Spring 2022 academic semester in one of these vaccination categories, and 288 remains in the same vaccination status throughout the semester. We do not consider vaccine mandates, but model the 289 vaccination coverage of the campus population, that is, the proportion boosted/proportion vaccinated. Because the 290 vaccinated individuals (i.e., without a booster) are assumed to have received their second dose more than four months 291 prior to the start of the spring semester, we also model the waning protection from the vaccine, in terms of reduced 292 vaccine effectiveness. 293
- Routine screening excludes subjects who are symptomatic (symptomatic testing is conducted separately), or who are in isolation, at the hospital, or who have tested positive for, and recovered from, the infection (i.e., "recovered and known" subjects). We study routine screening, with the specific strategy dictating the *screening population* (i.e., vaccination categories, or faculty versus student groups included in routine screening) and the *screening frequency* of each vaccination category, or faculty/student group. The screening strategy can be *universal* across all groups and vaccination status rategories, or *customized*. We study various screening policies, presented below in increasing level of customization, see Table 1.

All screening is conducted via the COVID-19 PCR test, which is the primary test used to detect SARS-CoV-2 [44], and subjects ³⁰¹ receive their test result 8 hours after taking the test, with a positive test result immediately leading to isolation. All false ³⁰² positives are corrected the next day (through additional testing). We assume perfect compliance for all isolation orders and face ³⁰³ masking policies, and model imperfect compliance for routine screening. ³⁰⁴

Setting and Parameters: We simulate the infection spread in our hypothetical college of 24,000 (22,500 students and 2,500 students and 2,500 faculty members), with 135 students and 9 faculty members (0.6% of each group) having undetected, asymptotic SARS-CoV-2 infection at the outset, and some individuals arriving on campus as vaccinated or boosted. The study period is an 80-day Spring acceleration of the details are provided in the Supplementary information.

A unique feature of our model is that the two variants, Delta and Omicron, can potentially be in circulation simultaneously, 310 and parameter ω_0 represents the proportion (in %) of all COVID-19 infections caused by Omicron $(1 - \omega_0)$ represents the 311 proportion caused by Delta). The basic reproduction number (R0) varies with both groups (faculty versus student) and variant 312 (Delta versus Omicron), while vaccine effectiveness against symptom development (ε) and hospitalization (υ) vary with both 313 vaccination status (vaccinated versus boosted) and variant (Delta versus Omicron). To reflect these characteristics in our model, 314 we compute the basic reproduction number per group, and vaccine effectiveness per vaccination status, as weighted averages 315 of their respective values for each variant, that is, as a function of ω_0 – see Table 3, which provides the key parameters, the 316 weighted average formula, and the computed parameters for the $\omega_0 = 50\%$ case, considering a 3:1 ratio between the R0 values 317 for Omicron and Delta [45, 46, 47]. While these numbers may seem high for the general population, they are more relevant for 318 the college campus setting [48]. 319

Outcome Measures of Interest: Total infections, hospitalizations, deaths by group (student versus faculty) and by vaccination status over the 80-day semester; peak daily new infections, peak daily hospitalizations; average number of screening tests per day; number of infections, or peak infections, averted per 1,000 tests compared to the no screening scenario.

Sensitivity Analysis: We conduct various sensitivity analyses through varying the values for: the proportion of all COVID-19 infections caused by Omicron (versus Delta), vaccination coverage (proportion boosted/vaccinated), and screening compliance. We study the effectiveness of various universal and customized screening strategies (see Table 1), obtained by varying the screening frequency(ies) (every 1,2,3,7, 14 days, or no screening) for each vaccination status, see Table 2. Different strategies may require different numbers of tests, representing scenarios with different testing capacities or testing kits.

Statistical Analysis

The compartmental model is coded in C++, and the results are analyzed in Microsoft Excel, through various plots. Our analysis does not involve any statistical tests, therefore, we do not report statistical significance levels. 330

Code availability

 The codes used to generate the results are available at:
 332

 https://github.com/mjrabil/Screening-for-safe-opening-of-universities-under-Omicron-and-Delta-variants-of-COVID-19
 333

References

- 1. Nadworny, E. How colleges are dealing with high COVID case counts on campus (Accessed on January 2022). https: 335 //www.npr.org/2022/01/23/1072730869/omicron-college-campuses-covid-outbreaks. 336
- Johnson, A. G. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence—25 US jurisdictions, April 4–December 25, 2021.
 MMWR. Morb. Mortal. Wkly. Rep. 71 (2022).

328

331

3.	Iuliano, A. D. et al. Trends in disease severity and health care utilization during the early Omicron variant period compared	340
	with previous SARS-CoV-2 high transmission periods—United States, December 2020–January 2022. (2022).	341
4.	Accorsi, E. K. <i>et al.</i> Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. <i>JAMA</i> (2022).	342 343
5.	CDC. Variant proportions (Accessed on February 2022). https://covid.cdc.gov/covid-data-tracker/#variant-proportions.	344
6.	Abramson, A. Omicron vs. Delta: How the 2 COVID-19 variants compare, according to experts and research (Accessed on Eebruary 2022). https://www.bealth.com/condition/infectious_diseases/coronavirus/omicron_vs_delta	345
7.	Thompson, M. G. Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predomi-	346 347 348
8.	nance—VISION network, 10 states, August 2021–January 2022. <i>MMWR. Morb. Mortal. Wkly. Rep.</i> 71 (2022). Kirzinger, A., Kearney, A., Hamel, L. & Brodie, M. KFF COVID-19 vaccine monitor: Early Omicron update (Accessed on February 2022). https://www.kff.org/coronavirus-covid-19/poll-finding/ kff-covid-19-vaccine-monitor-early-omicron-update/.	349 350 351 352
9.	Alonso, M. Amazon, Walmart and pharmacies are limiting the number of at-home COVID tests you can buy (Accessed on February 2022). https://www.cnn.com/2021/12/21/business/cvs-walgreens-covid-test-limit/index.html.	353 354
10.	Gao, Z. <i>et al.</i> A systematic review of asymptomatic infections with COVID-19. <i>J. Microbiol. Immunol. Infect.</i> 54 , 12–16 (2021).	355 356
11.	Paltiel, A. D., Zheng, A. & Walensky, R. P. Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States. <i>JAMA network open</i> 3 , e2016818–e2016818 (2020).	357 358
12.	Shahangian, S. Laboratory-based health screening: Perception of effectiveness, biases, utility, and informed/shared decision making. <i>Lab. Medicine</i> 37 , 210–216 (2006).	359 360
13.	Deckert, A., Bärnighausen, T. & Kyei, N. N. Simulation of pooled-sample analysis strategies for COVID-19 mass testing. <i>Bull. World Heal. Organ.</i> 98 , 590 (2020).	361 362
14.	Wacharapluesadee, S. <i>et al.</i> Evaluating the efficiency of specimen pooling for PCR-based detection of COVID-19. <i>J. medical virology</i> 92 , 2193–2199 (2020).	363 364
15.	Du, Z. <i>et al.</i> Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. <i>The Lancet Public Heal.</i> 6 , e184–e191 (2021).	365 366
16.	Brooks-Pollock, E. <i>et al.</i> High COVID-19 transmission potential associated with re-opening universities can be mitigated with layered interventions. <i>Nat. communications</i> 12 , 1–10 (2021).	367 368

17.	Anderson, R. M. The impact of vaccination on the epidemiology of infectious diseases (Elsevier, 2016).	369
18.	Kahn, B., Brown, L., Foege, W. & Gayle, H. A framework for equitable allocation of COVID-19 vaccine. <i>Natl. Acad.</i> <i>Press.</i> (U.S.) (2020).	370 371
19.	Ko, Y., Lee, J., Kim, Y., Kwon, D. & Jung, E. COVID-19 vaccine priority strategy using a heterogenous transmission model based on maximum likelihood estimation in the Republic of Korea. <i>Int. journal environmental research public health</i> 18 , 6469 (2021).	372 373 374
20.	Matrajt, L. <i>et al.</i> Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination. <i>Nat. communications</i> 12 , 1–18 (2021).	375 376
21.	Viana, J. <i>et al.</i> Controlling the pandemic during the SARS-CoV-2 vaccination rollout. <i>Nat. communications</i> 12 , 1–15 (2021).	377 378
22.	Nastasi, G., Perrone, C., Taffara, S. & Vitanza, G. A time-delayed deterministic model for the spread of COVID-19 with calibration on a real dataset. <i>Mathematics</i> 10 , 661 (2022).	379 380
23.	Massonnaud, C. R., Roux, J., Colizza, V. & Crepey, P. Evaluating COVID-19 booster vaccination strategies in a partially vaccinated population: a modeling study. <i>Vaccines</i> 10 , 479 (2022).	381 382
24.	Demongeot, J., Griette, Q., Magal, P. & Webb, G. Modeling vaccine efficacy for COVID-19 outbreak in New York city. <i>Biology</i> 11 , 345 (2022).	383 384
25.	Mukherjee, U. K. <i>et al.</i> Evaluation of reopening strategies for educational institutions during COVID-19 through agent based simulation. <i>Sci. reports</i> 11 , 1–24 (2021).	385 386
26.	Faucher, B. <i>et al.</i> Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19. <i>Nat. communications</i> 13 , 1–11 (2022).	387 388
27.	Han, S. <i>et al.</i> Time-varying optimization of COVID-19 vaccine prioritization in the context of limited vaccination capacity. <i>Nat. communications</i> 12 , 1–10 (2021).	389 390
28.	Forde, J. E. & Ciupe, S. M. Modeling the influence of vaccine administration on COVID-19 testing strategies. <i>Viruses</i> 13 , 2546 (2021).	391 392
29.	Rabil, M. J., Tunc, S., Bish, D. R. & Bish, E. K. Benefits of integrated screening and vaccination for infection control. <i>PloS ONE</i> 17 , e0267388 (2022). Doi: https://doi.org/10.1371/journal.pone.0267388.	393 394
30.	Paltiel, A. D. & Schwartz, J. L. Assessing COVID-19 prevention strategies to permit the safe opening of residential colleges in Fall 2021. <i>Annals Intern. Medicine</i> (2021).	395 396

31.	31. Bouchnita, A., Fox, S. J., Lachmann, M., Herrera-Diestra, G. G. & Meyers, L. A. COVID-19 scenario projections: The					
	emergence of Omicron in the US-January 2022. (2022).	398				
32.	Lee, J. et al. Modelling the effects of social distancing, antiviral therapy, and booster shots on mitigating Omicron spread.	399				
	(2022).	400				
33.	Tchoumi, S. Y., Rwezaura, H., Diagne, M. L., González-Parra, G. & Tchuenche, J. Impact of infective immigrants on	401				
	COVID-19 dynamics. Math. Comput. Appl. 27, 11 (2022).	402				
34.	Reuters. U.S. CDC estimates Omicron variant to be 58.6% of cases, revises projection (Accessed on April 2022).	403				
	https://www.reuters.com/world/us/omicron-estimated-be-586-coronavirus-variants-us-cdc-2021-12-28/.	404				
35.	CDC. Variant proportions (Accessed on April 2022). https://covid.cdc.gov/covid-data-tracker/#variant-proportions.	405				
36.	Marabito, M. Physicians struggle against Omicron surge, confusing guidelines and lim-	406				
	ited resources (Accessed on April 2022). https://www.healio.com/news/primary-care/20220202/	407				
	physicians-struggle-against-omicron-surge-confusing-guidelines-and-limited-resources.	408				
37.	Ruhnke, G. W. COVID-19 diagnostic testing and the psychology of precautions fatigue. <i>Cleve Clin J Med</i> 19–21 (2020).	409				
38.	Boston University. Update on Omicron and COVID-19 protocols (Accessed on April 2022). https://www.bu.edu/dos/2022/	410				
	02/15/update-on-omicron-and-covid-19-protocols/.	411				
39.	SUNY Morrisville. Weekly testing requirements (Accessed on April 2022). https://www.morrisville.edu/coronavirus/	412				
	testing.	413				
40.	Emory University. COVID-19 testing (Accessed on April 2022). https://www.emory.edu/forward/covid-19/testing/index.	414				
	html.	415				
41.	Boston University. Updated guidance on Spring public health protocols and booster (Accessed on April 2022). https://www.april.com/april.	416				
	//www.bu.edu/dos/2022/01/10/updated-guidance-on-spring-public-health-protocols-and-booster/.	417				
42.	Stanford University. Testing and other COVID-19 updates (Accessed on April 2022). https://healthalerts.stanford.edu/	418				
	covid-19/2022/02/17/testing-and-other-covid-19-updates/.	419				
43.	Statista. Number of COVID-19 vaccine doses administered in the United States as of November 17,	420				
	2021, by vaccine manufacturer (Accessed on November 2021). https://www.statista.com/statistics/1198516/	421				
	covid-19-vaccinations-administered-us-by-company/.	422				
44.	Cleveland Clinic. COVID-19 and PCR testing (Accessed on June 2021). https://my.clevelandclinic.org/health/diagnostics/	423				
	21462-covid-19-and-pcr-testing.	424				

45.	Ito, K., Piantham, C. & Nishiura, H. Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with	425
	respect to the Delta variant in Denmark. J. medical virology (2021).	426
46.	Lyngse, F. P. et al. SARS-CoV-2 Omicron VOC transmission in Danish households. MedRxiv (2021).	427
47.	Liu, Y. & Rocklöv, J. The effective reproduction number for the Omicron SARS-CoV-2 variant of concern is several times higher than Delta. <i>J. travel medicine</i> (2022).	428 429
48.	Lu, H. <i>et al.</i> Are college campuses superspreaders? a data-driven modeling study. <i>Comput. methods biomechanics</i>	430
49.	CDC. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) variant cluster — Nebraska, November–December 2021 (Accessed on December 2021), https://www.cdc.gov/mmwr/volumes/70/wr/mm705152e3.htm.	431
50.	CDC. CDC updates and shortens recommended isolation and quarantine period for general population (Accessed on December 2021). https://www.cdc.gov/media/releases/2021/s1227-isolation-quarantine-guidance.html.	434
51.	Zha, W. T. <i>et al.</i> Research about the optimal strategies for prevention and control of varicella outbreak in a school in a central city of China: Based on an SEIR dynamic model. <i>Epidemiol. & Infect.</i> 148 (2020).	436 437
52.	Bruxvoort, K. J. <i>et al.</i> Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants of SARS-CoV-2: test negative case-control study. <i>BMJ</i> 375 (2021).	438 439
53.	Dyer, O. COVID-19: Omicron is causing more infections but fewer hospital admissions than Delta, South African data show (2021).	440 441
54.	Paul, M. Omicron protection from booster eases holiday worries (Accessed on January 2022). https://news.northwestern. edu/stories/2021/12/omicron-protection-from-booster-eases-holiday-worries/&fj=1.	442 443
55.	Poletti, P. <i>et al.</i> Association of age with likelihood of developing symptoms and critical disease among close contacts exposed to patients with confirmed SARS-CoV-2 infection in Italy. <i>JAMA network open</i> 4 , e211085–e211085 (2021).	444 445
56.	CDC. Demographic trends of COVID-19 cases and deaths in the US reported to CDC (Accessed on November 2021). https://covid.cdc.gov/covid-data-tracker/#demographics.	446 447
57.	COVID-Net. Laboratory-confirmed COVID-19-associated hospitalizations (Accessed on November 2021). https://gis.cdc. gov/grasp/COVIDNet/COVID19_3.html.	448 449
58.	Andrews, N. <i>et al.</i> Duration of protection against mild and severe disease by COVID-19 vaccines. <i>New Engl. J. Medicine</i> (2022).	450 451
59.	Statista. Number of Coronavirus disease 2019 (COVID-19) deaths in the U.S. as of November 24, 2021, by age* (Accessed on November 2021). https://www.statista.com/statistics/1191568/reported-deaths-from-covid-by-age-us/.	452 453

60.	Statista. Total number of cases of COVID-19 in the United States as of November 24, 2021, by age group (Accessed on	454
	November 2021). https://www.statista.com/statistics/1254271/us-total-number-of-covid-cases-by-age-group/.	455
61.	Stites, E. C. & Wilen, C. B. The interpretation of SARS-CoV-2 diagnostic tests. Med (2020).	456
62.	Woloshin, S., Patel, N. & Kesselheim, A. S. False negative tests for SARS-CoV-2 infection—challenges and implications.	457
	New Engl. J. Medicine 383 , e38 (2020).	458
63.	Yohe, S., of American Pathologists, C. et al. How good are COVID-19 (SARS-CoV-2) diagnostic PCR tests. Coll. Am.	459
	Pathol. (2020).	460
64.	Nietzel, M. T. Students and faculty are complying with college vaccination mandates (Accessed on April 2022). https://www.	461
	forbes.com/sites/michaeltnietzel/2021/09/02/students-and-faculty-are-complying-with-college-vaccination-mandates/	462
	?sh=2f5b1c9e35ec.	463
65.	Mauer, J. UA reports 58% student vaccination rate as campus cases double (Accessed on April 2022). https://cw.ua.edu/	464
	82637/news/ua-reports-58-student-vaccination-rate-as-campus-cases-double/.	465
66.	Mayo Clinic. U.S. COVID-19 vaccine tracker: See your state's progress (Accessed on April 2022). https://www.mayoclinic.	466
	org/coronavirus-covid-19/vaccine-tracker.	467
67.	Anderson, M. Only 40% of fully vaccinated Americans have received a booster shot, CDC says (Accessed on April 2022).	468
	https://fortune.com/2022/01/25/40-percent-fully-vaccinated-americans-booster-shot-cdc-report/.	469
68.	CDC. Trends in demographic characteristics of people receiving COVID-19 vaccinations in the United States (Accessed	470
	on April 2022). https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends.	471
69.	Virginia Tech. COVID-19 dashboard (Accessed on April 2022). https://ready.vt.edu/dashboard.html.	472
Au	thor contributions statement	473
M.J	.R wrote the first draft of the manuscript, coded the model, and produced the numerical results. S.T. supervised the coding	474
and	the visualization of the results. S.T, D.R.B, and E.K.B contributed to the research question, and the conceptualization and	475
sup	ervision of the work. All authors developed the research question and the methodology, analyzed the results, and reviewed	476
and	edited the manuscript.	477
Co	ompeting interests	478
Aut	hors have no conflict of interest to declare.	479
Su	pplementary Information	480
Sup	plementary Information.	481



Fig. 1 Number of infections averted per 1,000 tests with respect to the screening frequency of the unvaccinated, for various universal and customized screening strategies under various booster and vaccination coverages and Omicron proportions (unvac: unvaccinated, vac: vaccinated)



Fig. 2 Peak number of infections averted per 1,000 tests with respect to the screening frequency of the unvaccinated, for various universal and customized screening strategies under various booster and vaccination coverages and Omicron proportions (unvac: unvaccinated, vac: vaccinated)



Screen(unvac) Screen(unvac+vac) Screen(all) Screen(freq custom) Screen(full custom)

Fig. 3 Number of infections averted per 1,000 tests with respect to the screening frequency of the unvaccinated, for various customized screening strategies under 64% boosted, 18% vaccinated, 18% unvaccinated, and various Omicron proportions. (a)-(b): Screening is customized based on vaccination status only; the label represents the screening frequency for unvaccinated, vaccinated, boosted. (c)-(d): Screening is customized based on both vaccination status and faculty versus students; the label represents the screening frequency for unvaccinated students, vaccinated students, boosted students, unvaccinated faculty, vaccinated faculty, boosted faculty. ("-" indicates no screening.)



Fig. 4 Peak number of infections averted per 1,000 tests with respect to the screening frequency of the unvaccinated, for various customized screening strategies under 64% boosted, 18% vaccinated, 18% unvaccinated, and various Omicron proportions. (a)-(b): Screening is customized based on vaccination status only; the label represents the screening frequency for unvaccinated, vaccinated, boosted. (c)-(d): Screening is customized based on both vaccination status and faculty versus students; the label represents the screening frequency for unvaccinated students, vaccinated students, boosted students, unvaccinated faculty, vaccinated faculty, boosted faculty. ("-" indicates no screening).



Fig. 5 Total number of infections and hospitalizations with respect to the booster coverage under no screening and universal daily screening under 18% unvaccinated and remaining either boosted or vaccinated, and 100% screening compliance ($\eta = 100\%$) for: (a) $\omega_0 = 50\%$, (b) $\omega_0 = 95\%$.

Screening Strategy	Policy-maker's Decision			
No screening	• None			
Universal screening	• The common screening frequency			
Screening population	• Which vaccination categories to screen (unvaccinated, vaccinated, boosted)			
customization	• The common screening frequency for the screening population			
Screening population and	• Which vaccination categories to screen (unvaccinated, vaccinated, boosted)			
frequency customization	• A screening frequency for each vaccination category included in screening			
Full customization	Which vaccination categories (unvaccinated, vaccinated, boosted) and			
	groups (faculty versus students) to screen			
	• A screening frequency for each vaccination category & group (faculty versus			
	students) included in screening			

Table 1 Description of universal and customized screening strategies.

Table 2 Parameter Values and Ranges for Sensitivity Analysis.

Model Parameter Value(s)		Comments/References		
Disease dynamics		<u> </u>		
Proportion of infections	50%, 95%	Assumption with sensitivity		
due to the Omicron variant (ω_0)		analysis		
Mean latent time 3.5 days		Average of Delta (4 days) and Omicron (3 days), based on CDC [49], 2021		
Mean time to recovery 5 days		CDC [50], 2021		
Disease transmission				
Ratio of basic reproduction numbers -	3:1	Ito et al. [45], 2021, Scientific American [46], 2021 and		
Omicron:Delta		based on Liu & Rocklöv [47], 2022		
Inputs for basic reproduction number	of (variant, grou	p):		
Delta, students	6	Assumption		
Omicron, students	$3 \times 6 = 18$	Assumption		
Delta, faculty	3.2	Assumption		
Omicron, faculty	$3 \times 3.2 = 9.6$	Assumption		
Reduction in disease transmission rate	50%	Zhang et al. [51], 2020		
under a face mask policy (γ)				
Disease outcomes				
Vaccine effectiveness against infection	for (variant, vac	cination status):		
Delta, vaccinated	80%	Bruxvoort et al. [52], 2021		
Omicron, vaccinated	33%	BMJ [53], 2021		
Delta, boosted	86.7%	Bruxvoort et al. [52], 2021		
Omicron, boosted	69.4%	Paul [54], 2021		
Symptom development rate for infected	30%	Assumption (similar to Paltiel et al. [11], 2020),		
(all vaccination status)		also based on Poletti et al. [55], 2021		
Hospitalization rate for symptomatic	1.4% / 8.4%	CDC [56], 2021, COVID-Net [57], 2021,		
and unvaccinated (students/faculty)		Rabil et al. [29], 2021		
Vaccine effectiveness against hospitaliz	ation for sympto	omatic (variant, vaccination status):		
Omicron, vaccinated	70%	BMJ [53], 2021		
Delta, vaccinated	91.7%	Andrews et al. [58], 2022		
Omicron, boosted	93%	Based on Thompson et al. [7], 2022		
Delta, boosted	97.5%	Bruxvoort et al. [52], 2021		
Fatality rate for hospitalized	0.05%/2%	Rabil et al. [29], 2021,		
and unvaccinated (students/faculty)		Statista [59, 60], 2021		
Screening test characteristics	000			
Test sensitivity (sens)	80%	Based on Stites & Wilen [61], 2020 Woloshin		
	000	et al. [62], 2020, Yone [63], 2020		
Test specifity (<i>spec</i>) 98%		Yohe [63], 2020		
Coverage characteristics at the start of the semester				
Proportion of vaccinated	82%	Based on Nielzei [64], 2021, Mauer [65], 2021 and Mayo Clinic [66], 2022		
Proportion of boosted	38%	Dased on Virginia Tech [60] 2022 and CDC [68], 2022		
64%		Based on Virginia Tech [69], 2022 and CDC [68], 2022		
Sensitivity analysis Demometer		Values		
Faranieter Screening frequency		1 day 2 days 2 days 7 days 14 days		
Proportion of infections due to the Omior	on variant (@_)	1 uay, 2 uays, 5 uays, 7 days, 14 days		
Coverage (propertien beested/vessingted	on varialit (ω_0)	640% / 180% 280% / 440% 00% / 1000% 1000% / 00% / 00%		
at the start of the semester)		047071070, 307074470, 070710070, 100707070, 070707		
Screening compliance (n)		75% 90% 100%		
screening compnance (1)		15%, 90%, 100%		

Table 3 Weighted Average Computations for the Basic Reproduction Number and Vaccine Effectiveness Values when the Proportion of Infections Caused by Omicron (Delta) is $\omega_0 (1 - \omega_0)$

	Group	Omicron	Delta	Weighted average formula	$\omega_O = 50\%$ case
Basic reproduction	Students	$3 \times 6 = 18$	6	$R0^{\omega_O}_{(k,s)} = 6 \times (1 - \omega_O) + 18 \times \omega_O$	$R0_{(k,s)}^{\omega_O=50\%} = 12$
number (R0), $k \in \{u, v, b\}$	Faculty	$3 \times 3.2 = 9.6$	3.2	$R0_{(k,f)}^{\omega_O} = 3.2 \times (1 - \omega_O) + 9.6 \times \omega_O$	$R0_{(k,f)}^{\omega_O=50\%} = 6.4$
Vaccine effectiveness	Vaccinated	33%	80%	$\varepsilon_{\nu}^{\omega_{O}} = 80\% \times (1 - \omega_{O}) + 33\% \times \omega_{O}$	$\varepsilon_v^{\omega_O=50\%}=56.5\%$
against infection (ε)	Boosted	69.4%	86.7%	$\varepsilon_b^{\omega_O} = 86.7\% \times (1 - \omega_O) + 69.4\% \times \omega_O$	$\varepsilon_b^{\omega_0 = 50\%} = 78.05\%$
Vaccine effectiveness	Vaccinated	70%	91.7%	$\upsilon_{\nu}^{\omega_{O}} = 91.7\% \times (1 - \omega_{O}) + 70\% \times \omega_{O}$	$v_v^{\omega_0=50\%}=80.85\%$
against hospitalization (v)	Boosted	93%	97.5%	$v_b^{\omega_O} = 97.5\% \times (1 - \omega_O) + 93\% \times \omega_O$	$v_b^{\omega_0=50\%} = 95.25\%$